2 recruiting, 2 terminated, 1 active not recruiting, 1 completed. 6 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Recruiting 2, Terminated 2, Active not recruiting 1, Completed 1 |
| Phase 1 | 2 | Active not recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow Advanced Lung Carcinoma: new trials by email Literature Review of Advanced Lung Carcinoma trials Research Report on Advanced Lung Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced Esophagogastric, Hepatopancreaticobiliary, Colorectal or Lung Cancer Olanzapine, Placebo Administration, Questionnaire Administration - Advanced Malignant Solid Neoplasm, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | OHSU Knight Cancer Institute | 66 | 2024-07-17 | 2026-07-16 |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer Clinical Encounter, Home Health Encounter, Quality-of-Life Assessment - Advanced Anal Carcinoma, Advanced Biliary Tract Carcinoma | Phase 2 | Recruiting | Mayo Clinic | 220 | 2023-09-21 | 2026-11-06 |
| Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations silevertinib (BDTX-1535) monotherapy - Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer | Phase 1 / Phase 2 | Active not recruiting | Black Diamond Therapeutics, Inc. | 200 | 2022-03-31 | 2026-07-22 |
| A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer TQB3616 capsules, Anlotinib Hydrochloride capsules, Irinotecan Hydrochloride for Injection - Advanced Lung Carcinoma | Phase 2 | Terminated | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 21 | 2021-08-18 | 2026-04-13 |
| Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid Malignancies Anti-CTLA4 Monoclonal Antibody BMS-986218, Nivolumab, Stereotactic Body Radiation Therapy - Advanced Lung Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 13 | 2021-03-29 | 2026-03-03 |
| Efficacy and Safety of First-line Anti-PD-1/PD-L1 Monoclonal Antibody in Combination With Chemotherapy and Bronchoscopy-assisted Interventional Therapy in Patients With Advanced Central Non-small Cell Lung Cancer Chemoimmunotherapy (CIT): Sintilimab + Platinum-Based Doublet Chemotherapy - Advanced Lung Carcinoma, Non-small Cell Lung Cancer | Phase 2 / Phase 3 | Completed | Shanghai Pulmonary Hospital, Shanghai, China | 33 | 2021-01-20 | 2026-07-21 |
Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Adrenal Gland Neoplasms (1) · Anorexia (1) · Brain Neoplasms (1) · Cachexia (1) · Carcinoma, Hepatocellular (1) · Colorectal Neoplasms (1) · Esophageal Neoplasms (1) · Liver Neoplasms (1) · Multiple Myeloma (1) · Myelodysplastic Syndromes (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Weight Loss (1)
Neoplasms (4) · Neoplasms by Site (4) · Lung Diseases (3) · Respiratory Tract Diseases (3) · Respiratory Tract Neoplasms (3) · Thoracic Neoplasms (3) · Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Neoplasms by Histologic Type (2) · Pathological Conditions, Signs and Symptoms (2) · Adenocarcinoma (1) · Adrenal Gland Diseases (1) · Blood Protein Disorders (1)
Home Care Services (1) · House Calls (1) · Injections (1) · Irinotecan (1) · Nivolumab (1) · Olanzapine (1) · Radiosurgery (1)
Black Diamond Therapeutics, Inc. (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · M.D. Anderson Cancer Center (1) · Mayo Clinic (1) · OHSU Knight Cancer Institute (1) · Shanghai Pulmonary Hospital, Shanghai, China (1)
United States (4) · China (2)
Eric Roeland, M.D., FAAHPM, FASCO (1) · James Welsh (1) · Roxana S. Dronca, MD (1)
P30CA069533 (1)